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Available online xxxxBackground: There is limited data on the impact of calcium (Ca) on acute procedural and clinical outcomes in
patients with lesions treated with bioresorbable vascular scaffolds (BRS). We sought to evaluate the effect of
calcium on procedural and clinical outcomes in a ‘real world’ population.
Methods: Clinical outcomes were compared between patients with at least 1 moderately or heavily calciﬁed
lesion (Ca) and patients with no/mild calciﬁed lesions (non-Ca) enrolled in our institutional BRS registry.
Results: 455 patients (N) with 548 lesions (L) treated with 735 BRS were studied. Patients in the Ca group (N =
160, L = 200) had more complex (AHA B2/C lesion: 69.0% in Ca vs 14.9% in non-Ca, p b 0.001) and signiﬁcantly
longer lesions (27.80± 15.27 vs 19.48± 9.92mm, p b 0.001). Overall device success rate was 99.1%with no sig-
niﬁcant differences between the groups. Despite more aggressive lesion preparation and postdilation compared
to non Ca, acute lumen gainwas signiﬁcantly less in Ca lesions (1.50 ± 0.66 vs 1.62 ± 0.69mm, p= 0.040) with
lower ﬁnal MLD (2.28 ± 0.41 vs 2.36 ± 0.43, p = 0.046). There were no signiﬁcant differences in all-cause
mortality, total deﬁnite scaffold thrombosis (ST), target lesion revascularization andmyocardial infarction between
the 2 groups. Late ST was more frequent in the Ca group compared to non Ca group (late ST: 2.1 vs 0%, p = 0.02).
Conclusions: Clinical outcomes after BRS implantation in calciﬁed and non-calciﬁed lesions were similar. A remark-
able difference in timing of thrombosis was observed, with an increased rate of late thrombosis in calciﬁed lesions.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Bioresorbable scaffolds (BRS) have beendeveloped as an alternative to
metallic stents as the need formechanical support for the treated vessel is
temporary, and beyond theﬁrst fewmonths there are potential disadvan-
tages of a permanentmetallic prosthesis. In earlier studies to demonstrate
Absorb BRS feasibility and safety, severe calciﬁcation was an exclusion
criterium [1–6]. Calciﬁed lesions may be challenging and encountered in
up to 35% of patients who undergo percutaneous coronary intervention
(PCI) [7–8]. Lesion calciﬁcation has been associated with increased PCI
complexity with worse procedural outcomes compared to non-calciﬁeds; Ca, calcium; DOCE, device
e cardiovascular events; MI,
PCI, percutaneous coronary
ts; QCA, Quantitative Coronary
thrombosis; TLR, target lesion
logy, Thoraxcentre, Erasmus
Rotterdam, The Netherlands.
Geuns).
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7), https://doi.org/10.1016/j.ilesions [9]. Wire crossing, delivery of equipment during pre and post
dilation and stent delivery may be more cumbersome. In calciﬁc lesions,
the effect of acute plaque recoil may affect stent expansion and is
associated with adverse clinical and angiographic outcomes [10–11].
Currently there is still limited data on the impact of calcium (Ca) on
acute procedural and clinical outcomes in patients with lesions treated
with BRS. We sought to determine the impact of calciﬁcation on acute
angiographic and 2 year clinical outcomes of a large cohort of patients
treated solely with the Absorb Bioresorbable Vascular Scaffold (BVS)
system (Abbott Vascular, Santa Clara, CA, USA).
2. Methods
This is an investigator-initiated, prospective, single-center, single-arm study evaluat-
ing performance of the Absorb BVS in lesions representative of daily clinical practice, in-
cluding calciﬁed lesions, total occlusions, long lesions and small vessels [12–13]. The
study inclusion period was from September 2012 till January 2015. Inclusion criteria
were patients presentingwith STEMI [12], NSTEMI, stable/unstable angina, or silent ische-
mia caused by a de novo stenotic lesion in a native previously untreated coronary artery
[13]. Procedural and long-term clinical outcomes were assessed. The primary endpoint
was major adverse cardiac events, deﬁned as a composite of cardiac death, myocardial
infarction and target lesion revascularization.rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
l and clinical outcomes in lesions treated with bioresorbable vascular
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Table 1A
Demographic characteristics of the study population.
BRS (N = 455; L = 548)
Patients with at least
1 calciﬁed lesion
(N = 160/35.2%;
L = 200/36.5%)
Patients with no
calciﬁed lesions
(N = 295/64.8%;
L = 348/63.5%)
Age 62.12 ± 10.64 56.54 ± 10.25 b0.001
Male 122/160 (76.3) 220/295 (74.6) 0.734
Ex/active smoker 81/160 (50.7) 181/294(61.6) 0.064
Diabetes mellitus 31/160 (19.4) 40/295 (13.6) 0.107
Dyslipidemia 75/158 (47.5) 109/288 (37.8) 0.056
Hypertension 93/159 (58.5) 139/290 (47.9) 0.038
Family history 55/160 (34.4) 127/295 (43.1) 0.206
CVA/TIA 13/160(8.1) 16/295 (5.4) 0.260
Prior MI 26/160 (16.3) 27/295 (9.2) 0.032
Prior PCI 10/160 (6.3) 20/295 (6.8) 1.000
Prior CABG 1/160 (0.6) 0 0.352
Kidney disease 11/160 (6.9) 8/295 (2.7) 0.048
Heart failure 7/160 (4.4) 7/295 (2.4) 0.262
Clinical presentation 0.002
Stable angina 53/160 (33.1) 63/295 (21.4)
Unstable angina 14/160 (8.8) 32/295 (10.8)
STEMI 40/160 (25.0) 118/295 (40.0)
NSTEMI 51/160 (31.9) 82/295 (27.8)
CCF/others 2/160 (1.3) 0
Disease involvement 0.060
SVD 97/160 (60.6) 210/295 (71.2)
DVD 42/160 (26.3) 63/295 (21.4)
LM/TVD 21/160 (13.1) 22/295 (7.4)
Values are expressed in numbers (percentages) or mean ± standard deviation when
appropriate.
2 J.M. Fam et al. / International Journal of Cardiology xxx (2017) xxx–xxx2.1. Ethics
This is an observational study, performed according to the privacy policy of the
Erasmus MC, and to the Erasmus MC regulations for the appropriate use of data in
patient-oriented research, which are based on international regulations, including the
declaration of Helsinki. Approval of the ethical board of the Erasmus MC was obtained.
All patients undergoing clinical follow-up provided written informed consent for the PCI
and to be contacted regularly during the follow-up period of the study.
2.2. Quantitative Coronary Analysis (QCA)
The angiographic analysis was performed by three independent investigators.
Coronary angiograms were analyzed with the CAAS 5.10 QCA software (Pie Medical BV,
Maastricht, the Netherlands). The QCA (Quantitative Coronary Analysis) measurements
provided reference vessel diameter (RVD), percentage diameter stenosis and minimal
lumen diameter (MLD). Acute gain was deﬁned as post-procedural MLD minus
pre-procedural MLD (in an occluded vessel MLD value was zero by default).
2.3. Angiographic assessment of lesion calciﬁcation
Lesion calciﬁcation was recognized as radio-opacities within the vessel wall at the
treated lesion. Calciﬁcation was categorized as either none/mild or moderate if the
radio-opacities were noted only during the cardiac cycle before contrast injection and
further classiﬁed as either none/mild or moderate based on visual assessment. Severe
calciﬁcationwas deﬁned as havingmultiple persisting (that are noted evenwithout cardi-
ac motion) opaciﬁcations of the coronary wall and visible in more than one projection,
surrounding the complete lumen of the coronary artery at the site of the lesion as per
SYNTAX deﬁnition (www.syntaxscore.com). Angiographic assessment of calciﬁcation
was conducted independently by 2 cardiologists. In cases of disagreement, a third
independent cardiologist reviewed the ﬁlms and provided a ﬁnal diagnosis.
2.4. Follow-up
Clinical demographic data of all patientswere obtained frommunicipal civil registries.
Follow-up information speciﬁc for hospitalization and cardiovascular events was obtained
through questionnaires. If needed, medical records or discharge letters from other hospitals
were requested. Events were adjudicated by an independent clinical events committee
(CEC). All information concerning baseline characteristics and follow-up was gathered in a
clinical data management system. Only patients who had given written consent for follow
up were included in the clinical outcome assessments.
2.5. Deﬁnitions
The primary endpoint was major adverse cardiovascular events (MACE), deﬁned as
the composite endpoint of cardiac death, myocardial infarction (MI) and target lesion
revascularization (TLR). The secondary endpoints were device oriented composite
endpoints (DOCE: composite of cardiac death, target vessel myocardial infarct and clinically
indicated target lesion revascularization) and patient oriented composite endpoints (POCE:
composite of all-cause mortality, all-cause myocardial infarct and any revascularization).
Deaths were considered cardiac unless a non-cardiac cause was deﬁnitely identiﬁed. TLR
was described as any repeated revascularization of the target lesion. Target vessel revascular-
ization (TVR) was deﬁned as any repeat percutaneous intervention or surgical bypass of any
segment of the target vessel. Non-target vessel revascularizationwas described as any revas-
cularization in a vessel other than the target lesion. Scaffold thrombosis (ST) and MI were
classiﬁed according to the Academic Research Consortium (ARC) [14]. Clinical device success
was deﬁned as successful delivery and deployment of the ﬁrst study scaffold/stent at the
intended target lesion and successful withdrawal of the delivery system with attainment of
ﬁnal in-scaffold/stent residual stenosis of b30% as evaluated by QCA. Clinical procedure
success was described as device success without major peri-procedural complications or
in-hospital MACE (maximum of 7 days).
2.6. Statistical analysis
Categorical variables are reported as counts and percentages, continuous variables as
mean ± standard deviation. The cumulative incidence of adverse events was estimated
according to the Kaplan-Meier method. Patients lost to follow-up were considered at
risk until the date of last contact, at which point they were censored. A cox regression
was performed to investigate clinical outcomes at two years, with the binary variable
calciﬁcation (yes/no). Adjusted cox regression were performed using fourteen patient
and lesion factors (see Online Supplement Table 1) to account for baseline differences
between patients with at least 1 moderately or heavily calciﬁed lesion (Ca) and patients
with no/mild calciﬁed lesions (non-Ca). Statistical analyses were performed using SPSS,
version 21 (IL, US). All statistical tests were two-sided and the p value of b0.05 was
considered statistically signiﬁcant.
3. Results
Baseline clinical characteristics are shown in Table 1A. A total of 548
lesions in 455 patients were studied of which 200 (36.5%) lesions in 160Please cite this article as: J.M. Fam, et al., Impact of calcium on procedura
scaffolds - A prospective..., Int J Cardiol (2017), https://doi.org/10.1016/j.ipatients (35.2%) were moderately or heavily calciﬁed (Ca group)
(Table 1A). Patients in the Ca group were older, with more hyperten-
sion, and kidney disease. In the calciﬁed cohort, there were 1.24 lesions
per patient. Lesion and QCA characteristics are as shown in Table 1B. The
left anterior descending artery (n= 254, 46.4%) was themost commonly
treated vessel in the study population. Lesions in the Ca groupweremore
complex (AHA B2/C lesion: 69.0% in Ca vs 14.9% in non-Ca, p b 0.001) and
signiﬁcantly longer. Compared to non-Ca group, lesions in the Ca groups
had smaller RVD and lower percentage diameter stenosis.
Procedural characteristics are as shown in Table 1C. Ca lesions were
treated with more aggressive lesion preparation compared to non Ca as
evidenced by themore signiﬁcant use of predilation, rotational atherec-
tomy and scoring balloon. The use of buddy wires was higher in Ca
lesions compared to non Ca lesions. Fig. 1A illustrates the satisfactory
expansion with minimal eccentricity on OCT of a calciﬁed LAD treated
with a BRS. Fig. 1B and C illustrates the acute and 2 year angiographic
and IVUS result respectively after rotational atherectomy and lesion
preparation followed by BRS implantation in a calciﬁed coronary artery.
A total of 735 scaffolds were implanted in the study population with
more scaffolds per lesion for Ca lesions (1.58 vs 1.21). Scaffold diameter
was similar in the two groups however scaffold length implanted was
longer in the Ca group. Postdilation was more frequently used in the
Ca group (Ca vs non Ca: 64.8% vs 42.1%, p b 0.001).
Procedural outcomes are shown in Table 2A. Post procedure, acute
lumen gain was signiﬁcantly less in Ca compared to non-Ca lesions
(1.50 ± 0.66 vs 1.62 ± 0.69 mm, p = 0.040) with lower ﬁnal MLD
(2.28 ± 0.41 vs 2.36 ± 0.43, p = 0.046). RVD and percentage diameter
stenosis were smaller in the Ca group compared to the non Ca group
though the differences did not reach statistical signiﬁcance. Procedural
success was high for both patient groups (98.7 and 99.7%, p = 0.25).
Overall device success rate and ﬁnal TIMI 3 ﬂow result were similar in
the two groups.
Wewere able to obtainwritten consent for the followup program in
395 patients (86.8%). Clinical outcomes were available in all (100%) of
these patients (Table 2B). These patient had similar baseline and proce-
dural characteristics as the total population. Kaplan-Meier curves forl and clinical outcomes in lesions treated with bioresorbable vascular
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Crude cumulative event rates at two years for the secondary endpoints,
described as Kaplan-Meier estimates are as shown in Table 2B. There
was a slight trend for higher events on cardiac death and all-cause mor-
tality for patients with calciﬁed lesions. No difference was observed in
POCE and DOCE. Though deﬁnite ST rates were similar between the
two groups (Fig. 2B), there was a remarkable variation in acute and
late deﬁnite ST. For acute deﬁnite ST, the incidence was higher in the
non-Ca lesions; for late deﬁnite ST there was a signiﬁcant increase in
Ca group compared to non-Ca group (late ST: 2.1% vs 0, p = 0.02) but
not for very late ST (Table 2B). After adjusting for difference in baseline
characteristics, Ca lesions was not found to be a signiﬁcant predictor of
any clinical events (Table 2C).
4. Discussion
In our study, the key ﬁnding was that despite Ca lesions were more
complex, required more lesion preparation, and encountered more
deliverability issues with lower acute luminal gain and smaller ﬁnal
MLD, acute procedural and 24 month clinical outcomes were similar
regardless of the calciﬁcation group with the exception of a higher
rate of late ST at 2 years in the Ca group compared to non-Ca group.
While there have been earlier studies evaluating the use of BRS in calci-
ﬁed lesions. [15–17], this is the ﬁrst large clinical prospective registry
study involving BRS scaffolds that look at the impact of lesion calciﬁca-
tion on long term clinical outcomes at 2 years.
Our ﬁndings, which showed that Ca lesions weremore complex and
required more careful and elaborate lesion preparation including rota-
tional atherectomy (in 5.5% of the lesions), were consistentwith similar
ﬁndings published elsewhere [9,18]. The use of intracoronary imaging
like IVUS was also increased in Ca lesions compared to non Ca lesions.
The more frequent use of buddy wires in the Ca group suggested that
difﬁcult deliverability issues may be encountered more commonly in
Ca lesions thus potentially prolonging procedure times. Despite the
advances in interventional techniques, calciﬁc lesions still pose a chal-
lenge for the procedurist. Due to their inherent polymeric structuralTable 1B
Lesion characteristics of the study population.
BRS (L = 548) p value
Calciﬁed lesions
(L = 200/36.5%)
Non calciﬁed lesions
(L = 348/63.5%)
Target vessel
LAD 126/200 (63.0) 128/348 (36.8) b0.001
LCX 27/200 (13.5) 96/348 (27.6) b0.001
RCA 42/200 (21.0) 111/348(31.9) 0.007
Diagonal 4/200 (2.0) 13/348(3.7) 0.314
Left main 1/200 (0.5) 0 0.365
SVG 0 0 –
Lesion AHA b0.001
A 5/200 (2.5) 71/348 (20.4)
B1 60/200 (30.0) 226/348 (64.9)
B2 85/200 (42.5) 46/348 (13.2)
C 53/200 (26.5) 6/348 (1.7)
Bifurcation 61/199 (31.7) 58/347 (16.7) b0.001
CTO 13/200 (6.5) 4/348 (1.1) 0.001
TIMI
Pre-procedure 0.074
TIMI 0 35/200 (17.5) 87/344 (25.0)
TIMI 1 6/200 (3.0) 17/344 (4.9)
TIMI 2 50/200 (14.4) 50/344 (14.4)
TIMI 3 125/200 (62.5) 190/344 (54.6)
QCA analysis
Pre-procedure
Treatment length 27.80 ± 15.27 19.48 ± 9.92 b0.001
RVD (mm) 2.52 ± 0.57 2.62 ± 0.57 0.053
MLD (mm) 0.85 ± 0.47 0.75 ± 0.55 0.036
Diameter stenosis (%) 65.39 ± 18.68 70.78 ± 20.98 0.004
Values are expressed in numbers (percentages) or mean ± standard deviation when
appropriate.
Please cite this article as: J.M. Fam, et al., Impact of calcium on procedura
scaffolds - A prospective..., Int J Cardiol (2017), https://doi.org/10.1016/j.icomposition and increased strut thickness, BRS have been shown to
have less favorablemechanical characteristics including less deliverabil-
ity and radial strength compared to current second generation DES [18,
19]. There have been concerns as to whether such mechanical
characteristics may result in less optimal stent performance which may
be more pronounced in calciﬁed lesions where focal areas of calciﬁcation
limit expansion of the BRS more compared to DES [18]. This may have
practical clinical implications since suboptimal stent expansions has
been known to contribute to metallic stent failure [20] and there have
been reports of inadequate scaffold expansion in BRS failure [21,22].
Our ﬁndings are also consistentwith clinical [23,24] data addressing
the feasibility of BRS in calciﬁed lesions. In a recent study looking at spe-
ciﬁc procedural outcomes in 62 calciﬁed lesions by Panoulas et al. [23], ex-
pansion of BRS as measured in terms of lumen gain on QCA and
intravascular ultrasound (IVUS) was similar between calciﬁed and
non-calciﬁed lesions. Acute luminal gain (1.83 ± 0.6 vs 1.86 ± 0.6 mm,
p = 0.732) and angiographic success were similar (98% non-calciﬁc vs
95.2% calciﬁc, p = 0.369), whereas procedural success was reduced in
patients with calciﬁc lesions (94.1% vs 83.9%, p = 0.034) due to higher
rates of periprocedural myocardial infarction (MI) (5% vs 13.1%, p =
0.067). MACE rates (10.9% non-calciﬁc vs 12.9% calciﬁc, p log-rank =
0.546)were similar in themedian follow-up time of 14months. However
a greater degree of lesion preparation in calciﬁed lesions was also
required. OCT was not used and a comparison of the expansion of BRS
compared with DES was not performed. In our study, we report 2 year
clinical outcomes in a larger study population which showed MACE
rates were similar between Ca and non-Ca groups. In another study
conducted by Kawamoto et al. [24], though eccentric calcium distribution
resulted in asymmetric expansion of BRS, the ﬁnal MSA was still compa-
rable irrespective of calcium distribution, and the use of IVUS for scaffold
optimization led to favorable clinical outcomes even in calciﬁed lesions.
Earlier OCT ﬁndings published from our center [25] also suggest that
regardless of the degree of angiographic calciﬁcation, BRS can achieve a
similar expansion as DES, in the context of an imaging-guided strategy
with adequate lesion preparation. Our ﬁndings were also consistent
with recent published literature showing that the presence of moderate
or severe lesion calciﬁcation does not negatively affect angiographic
outcomes at both post-procedure and 13-month follow-up after BVS
implantation [26]. However, in this study [26], heavily calciﬁed lesions
or those requiring extensive lesion preparation such as rotational atherec-
tomy were excluded according to the study protocol whereas our study
included “all comers” lesions with various degrees of calciﬁcation or
that require rotational atherectomy.
However, BRS deployment requires more lesion preparation and
decalciﬁcation strategy particularly for moderately or heavily calciﬁed
lesions. Further studies are needed to ascertain if in such lesions the
use of such a strategy may impact on long term clinical outcomes such
as increased TLR rates such as seen in DES deployment after lesion
debulking or decalciﬁcation using rotational atherectomy [27,28]. In
addition, the postdilation rate reported in our study (Table 1C) was
comparable to other studies considering that systematic postdilation
was implemented on average in b50% of previously published studies
[29]. It is still debatable if pursuing a systematic postdilation strategy
will have an impact on long term results particularly the risk of very
late ST (VLST). Given the results of this study, an analysis of BRS speciﬁc
implantation technique such as PSP (Prepare the lesion to be
reengineered; Size the vessel appropriately; Postdilate to embed scaf-
fold struts into the vessel wall) would be timely and of interest [30].
Though the lesions treated in the Ca group were more complex, requir-
ing longer andmore overlapping scaffolds and the post dilatation rate of
64.8% was considered relatively low for calciﬁc lesions, the procedural
and clinical results were still similar between the Ca and non Ca groups.
This may be reassuring since the current practice suggest a large use of
postdilation especially in stable patients with complex lesions.
BRS offers several unique potential advantages over DES. The future
bioresorption of BRS permits potential future grafting of treatedl and clinical outcomes in lesions treated with bioresorbable vascular
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Table 1C
Procedural characteristics of the study population.
BRS (L = 548) p value
Calciﬁed lesions
(L = 200/36.5%)
Non calciﬁed lesions
(L = 348/63.5%)
Number of treated lesions per procedure 1.24 ± 0.48 1.17 ± 0.48 0.133
Aspiration thrombectomy 34/200 (17.1) 106/348 (30.5) 0.001
Rotational atherectomy 11/200 (5.5) 0/348 0.002
Scoring balloon 9/200 (4.5) 1/348 (0.3) 0.001
Intracoronary imaging
IVUS 30/199 (15.1) 30/348 (8.6) 0.023
OCT 62/200 (31.0) 95/348 (27.3) 0.378
Predilation performed 177/200 (88.5) 265/348 (76.1) b0.001
Max predilation diameter 2.66 ± 0.36 2.53 ± 0.42 0.002
Predilation balloon: artery ratio 1.08 ± 0.25 1.01 ± 0.23 0.005
Maximum predilation inﬂation pressure, atm 14.25 ± 3.35 13.56 ± 3.01 0.067
Buddy wire 23/199 (11.6) 22/347 (6.3) 0.036
Additional daughter catheter 3/199 (1.5) 3/348 (0.9) 0.673
Mean number of scaffold 1.58 ± 0.823 1.21 ± 0.53 b0.001
Number of scaffolds (total 735) 315 420 b0.001
0 1/200 (0.5) 1/348 (0.3)
1 117/200 (58.5) 289/348 (83.0)
2 56/200 (28.0) 47/348 (13.5)
3 18/200 (9.0) 7/348 (2.0)
4 8/200 (4.0) 4/348 (1.1)
Scaffold diameter, mm 3.11 ± 0.32 3.12 ± 0.38 0.615
Scaffold length implanted, mm 34.65 ± 19.94 23.84 ± 12.20 b0.001
Overlapping scaffolds 80/200 (40.0) 52/348 (15.0) b0.001
Maximum scaffold implantation pressure, atm 14.99 ± 1.88 14.86 ± 1.97 0.510
Postdilation performed 129/199 (64.8) 146/347 (42.1) b0.001
Postdilation balloon: mean scaffold diameter ratio 1.06 ± 0.15 1.07 ± 0.10 0.422
Max postdilation balloon, mm 3.31 ± 0.43 3.31 ± 0.44 0.906
Maximum postdilation inﬂation pressure, atm 16.27 ± 3.63 15.83 ± 3.97 0.496
Values are expressed as numbers (percentages) or mean ± standard deviation when appropriate.
4 J.M. Fam et al. / International Journal of Cardiology xxx (2017) xxx–xxxsegments, allows potential reopening of “jailed” side branches and
potential recovery of vasomotor function and vessel remodeling.
These beneﬁts would bemore pertinent in patients with calciﬁc lesions,Fig. 1.A. Implantation of Bioresorbable vascular scaffold (BRS in calciﬁed left anterior descendin
Absorb™ BVS deployed in an overlapping manner-indicated in yellow) in a calciﬁed left anteri
preprocedure (Panel 1-2), after predilationwith a 2.5mmballoon at (Panel 1-3) and after postd
OCT performed showed that the scaffold was well expanded and apposed with no signiﬁca
respectively. The minimal lumen area (MLA) was 4.5 mm2 (2.83 × 1.81 mm) with an eccent
vessel in Panel 1-4. Panel 2-D showed the BRS implanted in a calciﬁed segment of the treat
longitudinal pullback of the treated vessel. B. Angiogram and intravascular ultrasound (IVUS)
right coronary artery (RCA). Panel 1-A shows the preprocedural angiogram at baseline with
(see insert). Panel 1-B shows the RCA post rotational artherectomy with 1.5 mm burr (see i
deployment of a BRS (BVS Absorb 3.0 × 28 mm - outlined in red). The borderline lesions in th
(white arrow). Panel 1-D shows the RCA at 2 years follow up which demonstrates that the
restenosis (outlined red). C. IVUS images of the RCA. The ﬁgure shows IVUS images of the cor
that the scaffold struts (white arrow) remained visible in the mid RCA with good apposition
remained widely patent with no signiﬁcant restenosis (Panels 2-1 and 2-2). + - Guidewire. (
the web version of this article.)
Please cite this article as: J.M. Fam, et al., Impact of calcium on procedura
scaffolds - A prospective..., Int J Cardiol (2017), https://doi.org/10.1016/j.iwho often have widespread disease resulting in long stented segments.
However whether these will translate into long term clinical beneﬁts in
more complex lesions such as thosewith signiﬁcant calciﬁcationswouldg artery (LAD). Panel 1. Implantation of bioresorbable vascular scaffolds (two 3.0 × 28mm
or descending artery (LAD). Calciﬁcation marked ‘+’ in Panel 1-1. Target lesion marked ‘*’
ilationwith a noncompliant 3.0mmballoon at high pressure (Panel 1-4).Panel 2A–E: Final
nt dissection seen. Proximal and distal reference areas were 7.21 mm2 and 5.52 mm2
ricity index (EI) of 0.63. Panel 2-A–C showed the corresponding segments of the treated
ed vessel with satisfactory expansion with minimal eccentricity. Panel 2-E showed the
of the right coronary artery (RCA). Angiogram and intravascular ultrasound (IVUS) of the
a severely tight lesion (circled) in the mid segment of the RCA which is heavily calciﬁed
nsert) and predilation with a Trek NC 3.25 mm balloon. Panel 1-C shows the RCA after
e ostium and mid right posterior descending artery (RPDA) was managed conservatively
previously deployed scaffold in the mid RCA was still widely patent with no signiﬁcant
responding segments of the RCA in Fig. 1B Panel 1-D at 2 years follow up demonstrating
and expansion with side branch (*-RPDA) patency and conﬁrmed the scaffolded vessel
For interpretation of the references to color in this ﬁgure legend, the reader is referred to
l and clinical outcomes in lesions treated with bioresorbable vascular
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Table 2A
Procedural outcomes of the study population.
BRS (L = 548) p value
Calciﬁed lesions
(L = 200/36.5%)
Non-calciﬁed lesions
(L = 348/63.5%)
TIMI postprocedure 0.850
TIMI 0 0 0
TIMI 1 1/200 (0.5) 2/348 (0.6)
TIMI 2 12/200 (6.0) 17/348 (4.9)
TIMI 3 187/200 (93.5) 329/348 (94.5)
QCA analysis post-procedure
RVD (mm) 2.75 ± 0.48 2.78 ± 0.45 0.401
MLD (mm) 2.28 ± 0.41 2.36 ± 0.43 0.046
Diameter stenosis (%) 16.71 ± 8.89 15.30 ± 8.61 0.069
Acute lumen gain 1.50 ± 0.66 1.62 ± 0.69 0.040
Procedural outcomes
Device success 197/200 (98.5) 346/348 (99.4) 0.208
Bailout by scaffold 6/200 (3.0) 5/348 (1.4) 0.439
Bailout by metallic stent 4/200 (2.0) 5/348 (1.4) 0.547
Intraprocedural thrombosis 1/200 (0.5) 1/348 (0.3) 1.000
Signiﬁcant dissection 14/200 (7.0) 16/348 (4.6) 0.444
Signiﬁcant no reﬂow/slow ﬂow 9/200 (4.5) 9/348 (2.6) 0.272
MLD: minimal lumen diameter; QCA: Quantitative Coronary Analysis; RVD: reference vessel
diameter. Values are expressed as numbers (percentages) or mean ± standard deviation
when appropriate.
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higher rate of ST related to the use of BRS [4,31–33], but did not provide
details on the effect of calciﬁcation. In our study, we see an observation
pattern of higher early ST cases in the non-Ca group followed by a signif-
icantly higher rate of late ST in the Ca group. To the best of our knowledge,
we believe the difference in timing on ST observed in the two groups is
notable and interesting which warrant further studies. The observation
of early ST in the non-Ca group (a group with a higher number of acute
coronary syndromes; ACS) patients might be related to scaffold under
sizing and to increasedplatelets activation. Predisposing factors of scaffold
undersizing include the increased thrombus burden and vasoconstriction
in the setting of acute STEMI leading to underestimation of the actual size
of the infarct-related artery, thus increasing the risk of the implantation of
undersized scaffolds which can be seen even in the setting of metallic
drug eluting stents [34]. Implantation of a relatively small scaffold in a rel-
atively larger vessel can result in incomplete apposition, predisposing to
ST [35]. Higher rates of ST were also previously noted in patients with
ACS which could be due to reduction of early neointimal growth and
strut coverage [36,37]. Reasons for the increase in late ST in the Ca com-
pared to the non Ca group include a role for technical factors such as sub-
optimal implantation with incomplete lesion coverage, underexpansion
and malapposition [35,38] and possibly greater impact on the scaffold
endothelization and resorption process from a reduced MLD in the Ca
group. The additional risks of late ST in the Ca lesions may arise from ei-
ther the loss of radial strength after scaffold resorption (which typically
commences 6 months to N1 year after scaffold implantation) or the scaf-
fold ‘dismantling’ around calciﬁed lesionswhichwill have forces localized
at the edge of the calciﬁed areaswhere expansion tends to be asymmet-
rical [24]. Scaffold ‘dismantling’ might result in rapid changes in vessel
wall architecture and therefore exert localized forces on the neointimal
coverage potentially resulting in microdissections, triggering the
thrombosis.
In our current study, though the event rate is similar between the Ca
and non Ca groups, this may also be partially attributed to a higher ACS
population in the non Ca group which is known to have higher risk of
clinical events at follow up. In an earlier study evaluating the one-year
outcomes in patients presenting with ACS compared to stable angina
patients after implantation of a BRS from our center, one-year clinical
outcomes in ACS patients treated with BRS were similar to non-ACS
patients. One-year deﬁnite ST rate was comparable: 2.0% for ACS popu-
lation versus 2.1% for stable population (p = 0.94), however, early ST
occurred only in ACS patients [39]. Comparatively, overall ST rates
were similar between the two groups in this study and further analysis
did not show that Ca lesions were a signiﬁcant predictor of ST
(Table 2C). Of note, there was no difference in VLST between the Ca
and non-Ca groups.
Though recent guidelines have supported a shift towards a shorter
duration of DAPT [40], our ﬁndings on an increased late ST rate in Ca le-
sionsmay suggest that a longer duration of DAPTmay still be necessary
if BRS is to be implanted before thepatient is to derive the potential ben-
eﬁts of BRS resorption. In our study, data on the use of dual antiplatelets
therapy (DAPT) were available in the 395 patients whose follow up
were available. All patients were prescribed aspirin during the duration
of the study. Second generation P2Y12 antiplatelet medications were
used; clopidogrel (n = 157, 39.7%), prasugrel (n = 187, 47.3%) and
ticagrelor (n = 51, 12.9%). The median duration of DAPT was 365.00
(IQR 364.00–394.50) days and was similar between the 2 groups. In a
study to evaluate the impact of DAPT termination on late and very late
ST in patients treated with the Absorb BRS, the incidence of ST was
low while on DAPT but potentially higher when DAPT was terminated
before 18 months [41,42]. Further studies may be required to evaluate
the effect of a prolonged duration of DAPT on the rate of late ST.
The ﬁndings showing a lesser acute lumen gain and similar 2 year
MACE were consistent with previous research involving metallic
DES in calciﬁed versus non calciﬁed lesions [8]. Moussa et al. reported
in a subanalysis of the TAXUS IV trial [8] a signiﬁcant reduction inPlease cite this article as: J.M. Fam, et al., Impact of calcium on procedura
scaffolds - A prospective..., Int J Cardiol (2017), https://doi.org/10.1016/j.ilate lumen loss in calciﬁc lesions (n = 247) treated with PES vs BMS
(0.26 ± 0.56 vs 0.51 ± 0.48 mm, p = 0.015). In a study from the
SPIRIT II trial by Onuma et al. [43], the efﬁcacy of EES in patients with at
least one angiographically deﬁned moderate calciﬁc lesion (68 patients),
was compared to those without any calciﬁc lesion (144 patients). Late
lumen loss was similar between the two groups at two years. No signiﬁ-
cant difference in two-year MACE rates was observed between the two
groups (calciﬁc vs non-calciﬁc: 10.9% vs 4.4%, p= 0.12). The numerically
increased MACE rate was attributed to an increased ischemia-driven TLR
(7.8% vs 1.5%, p= 0.03). However TLR rates were similar between the Ca
and non Ca groups in our study.
In summary, clinical outcomes of calciﬁed and non-calciﬁed lesions
treated with BRS are in general similar except for late ST. Overall two-
yearMACE rates appear acceptable in patients with andwithout calciﬁc
lesions treated with BRS. Further larger randomized controlled trials
comparing clinical outcomes of DES to BRS in calciﬁed lesions may
be required to evaluate the full impact of calcium on BRS outcomes
compared to DES.4.1. Study limitations
This is a single-center, single-arm registrywith nodirect comparison
with metallic DES. The total number of patients in this study was still
limited. In addition, calciﬁcation assessmentwas based on angiographic
classiﬁcation alone rather than characterization of coronary calciﬁcation
using alternative imaging modality such as intravascular ultrasound.
Thus, these ﬁndings warrant further conﬁrmation in a large-scale trial.
Furthermore, deciding which patient or lesion was suitable for treat-
ment with BRS could have resulted in selection bias. The event rate is
unknown in the patients (n = 60, 13.2%) who did not agree to partici-
pate in further follow up and hence excluded from clinical outcome
analysis. We further evaluated the population who did not agree to
further follow up and compared the baseline demographic, lesion and
procedural characteristics between the cases with calciﬁed lesions and
non-calciﬁed lesions. There were signiﬁcant differences in terms of
age and use of predilation between the 2 groups which were similarly
observed in the main population. Overall, the results are similar which
provide support to our inference that the clinical outcomes reported
in our study may be extrapolated to the patients whose clinical out-
comes were not available. In addition, as our study was not powered
to study clinical outcomes in relation to DAPT, we believe that furtherl and clinical outcomes in lesions treated with bioresorbable vascular
jcard.2017.08.046
Table 2B
Clinical endpoints at two years, described as Kaplan-Meier estimates.
Ca (n = 143) Non-Ca (n = 252) p value
MACE (%) 11.7 (17) 8.0 (19) 0.351
DOCE (%) 9.0 (12) 7.3 (17) 0.564
Cardiac death (%) 3.8 (5) 0.8 (2) 0.052
Target vessel MI 5.3 (7) 5.1 (12) 0.945
Clinically indicated TLR (%) 4.7 (6) 5.9 (14) 0.544
Deﬁnite ST (%) 2.1 (3) 2.4 (6) 0.856
Acute 0.0 1.2 (3) 0.191
Subacute 0.0 0.4 (1) 0.450
Late 2.1 (3) 0.0 0.020
Very late 0.0 0.8 (2) 0.287
Probable ST (%) 0.7 (1) 0.4 (1) 0.682
Acute 0.0 0.0
Subacute 0.0 0.0
Late 0.7 (1) 0.4 (1) 0.682
Very late 0.0 0.0
Deﬁnite/probable ST (%) 2.9 (4) 2.8 (7) 0.993
Acute 0.0 1.2 (3) 0.191
Subacute 0.0 0.4 (1) 0.450
Late 2.9 (4) 0.4 (1) 0.039
Very late 0.0 0.8 (2) 0.287
POCE (%) 12.2 (23) 17.2 (29) 0.211
All-cause mortality (%) 3.8 (6) 0.8 (3) 0.052
Any revascularization 12.2 (16) 10.3 (25) 0.714
TVR (%) 5.3 (7) 6.5 (16) 0.544
Non-TVR (%) 7.7 (10) 4.7 (11) 0.260
All cause MI (%) 8.3 (11) 6.5 (15) 0.509
DOCE: device oriented composite endpoints (composite of cardiac death, target vessel
myocardial infarct and clinically indicated target lesion revascularization); POCE: patient
oriented composite endpoints (composite of all - cause mortality, all cause myocardial
infarct and any revascularization). (Number of composite endpoints does not add up as
any patient may have multiple events.) Ca - calciﬁed lesions; non-Ca - non calciﬁed lesions.
Table 2C
Predictors for clinical outcomes at two years follow-up (using Cox regression), calciﬁed vs
non-calciﬁed lesions.
Unadjusted HR (95% CI) p-Value Adjusteda HR (95% CI) p value
All-cause death
Ca vs non-Ca 4.428 (0.859–22.822) 0.075 1.7 (0.263–10.994) 0.578
Cardiac death
Ca vs non-Ca 4.428 (0.859–22.822) 0.075 1.7 (0.263–10.994) 0.578
MACE
Ca vs non-Ca 1.378 (0.700–2.712) 0.353 0.850 (0.382–1.895) 0.692
MI
Ca vs non-Ca 1.393 (0.632–3.068) 0.411 0.944 (0.366–2.433) 0.905
TLR
Ca vs non-Ca 0.754 (0.290–1.963) 0.564 0.644 (0.225–1.845) 0.644
TVR
Ca vs non-Ca 0.762 (0.314–1.853) 0.549 0.629 (0.236–1.674) 0.353
Non-TVR
Ca vs non-Ca 1.627 (0.691–3.831) 0.265 0.950 (0.342–2.634) 0.921
Deﬁnite ST
Ca vs non-Ca 0.880 (0.220–3.518) 0.856 0.930 (0.206–4.234) 0.930
Probable ST
Ca vs non-Ca 1.771 (0.111–28.307) 0.686 0.917 (0.039–21.720) 0.957
Def/prob ST
Ca vs non-Ca 1.005 (0.294–3.434) 0.993 0.935(0.242–3.610) 0.922
DOCE
Ca vs non-Ca 1.242 (0.593–2.600) 0.566 0.961 (0.416–2.218) 0.926
POCE
Ca vs non-Ca 1.416 (0.819–2.448) 0.213 1.045 (0.556–1.963) 0.891
To account for baseline differences between patients with at least 1 moderately or
heavily calciﬁed lesion (Ca) andpatientswith no/mild calciﬁed lesions (non-Ca), covariate
adjustment using fourteen patient and lesion factors were used (see Online Supplement).
a Adjusted for gender, age, presentation with ACS, multivessel disease, diabetes
mellitus, dyslipidemia, smoking, hypertension, peripheral artery disease, small vessel,
bifurcation, average scaffold diameter per patient, total scaffold length per patient. DOCE:
device oriented composite endpoints (composite of cardiac death, target vesselmyocardi-
al infarct and clinically indicated target lesion revascularization); POCE: patient oriented
composite endpoints (composite of all - cause mortality, all cause myocardial infarct and
any revascularization). (Number of composite endpoints does not add up as any patient
may have multiple events.) Ca - calciﬁed lesions; non-Ca - non calciﬁed lesions; MACE -
major adverse cardiovascular events; MI - myocardial infarct; TLR - target lesion revascu-
larization; TVR - target vessel revascularization; ST - scaffold thrombosis.
6 J.M. Fam et al. / International Journal of Cardiology xxx (2017) xxx–xxxstudies may be required to evaluate if a prolonged duration of DAPT
may reduce late onset ST in calciﬁed lesions.
5. Conclusion
Careful more elaborate lesion preparation and the use of dedicated
devices, such as scoring balloons and rotational atherectomy and
intracoronary imaging were more likely encountered in Ca lesions.
Even after more lesion preparation, acute gain and resulting ﬁnal MLD
by BRS implantation was less compared to non-calciﬁed lesion. Clinical
outcomes of calciﬁed and non-calciﬁed lesions treated with BRS were
otherwise similar. However this is accomplished in the setting of appro-
priate case selection, adequate lesion preparation and scaffold optimiza-
tion with attention to an adequate duration of dual antiplatelet in lineFig. 2. Kaplan-Meier curve showing no signiﬁcant difference in A) MACE and B) deﬁnite ST a
bioresorbable vascular scaffolds (BRS). The primary endpoint was major adverse cardiovas
infarction (MI) and target lesion revascularization (TLR). Of note while the incidence of ac
increase in late ST in calciﬁed lesions compared to non-Ca lesions. ST - scaffold thrombosis.
Please cite this article as: J.M. Fam, et al., Impact of calcium on procedura
scaffolds - A prospective..., Int J Cardiol (2017), https://doi.org/10.1016/j.iwith guideline recommendations. Interestingly, a different pattern of
timing of ST was observed with no early ST but an increased late ST
rate when implanted in calciﬁed lesions.t 2 years in patients with calciﬁed (Ca) and non-calciﬁed (non-Ca) lesions treated with
cular events (MACE), deﬁned as the composite endpoint of cardiac death, myocardial
ute ST was higher in the non-Ca group compared to Ca group, there was a signiﬁcant
l and clinical outcomes in lesions treated with bioresorbable vascular
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Data on the impact of calcium (Ca) on outcomes in patients with
lesions treated with bioresorbable vascular scaffolds (BRS) is limited,
particularly in a “real world” study population. Careful more elaborate
lesion preparation and the use of dedicated devices, such as scoring
balloons and rotational atherectomy and intracoronary imaging were
more likely encountered in Ca lesions. Late ST was more frequent in
the Ca group compared to non-Ca group and no difference for VLST
was observed. Theﬁndingsmerit further evaluation of clinical outcomes
of BRS and the impact of implantation techniques in complex calciﬁed
lesions.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2017.08.046.
Conﬂict of interest
The authors acknowledged that BVS Expand and BVS STEMI are sup-
ported by research grants from Abbott Vascular. Prof van Geuns and
Yoshinobu Onuma received speaker’s fee from Abbott Vascular.
References
[1] C. Simsek, A. Karanasos, M. Magro, H.M. Garcia-Garcia, Y. Onuma, E. Regar, E.
Boersma, P.W. Serruys, R.J. van Geuns, Long-term invasive follow-up of the
everolimus-eluting bioresorbable vascular scaffold: ﬁve-year results of multiple
invasive imaging modalities, EuroIntervention (Oct 28 2014) https://doi.org/10.
4244/EIJY14M10_12 (Epub ahead of print).
[2] A. Karanasos, C. Simsek, M. Gnanadesigan, N.S. van Ditzhuijzen, R. Freire, J. Dijkstra,
S. Tu, N. Van Mieghem, G. van Soest, P. de Jaegere, P.W. Serruys, F. Zijlstra, R.J. van
Geuns, E. Regar, OCT assessment of the long-term vascular healing response
5 years after everolimus-eluting bioresorbable vascular scaffold, J. Am. Coll. Cardiol.
64 (22) (Dec 9 2014) 2343–2356.
[3] P.W. Serruys, J.A. Ormiston, Y. Onuma, E. Regar, N. Gonzalo, H.M. Garcia-Garcia, K.
Nieman, N. Bruining, C. Dorange, K. Miquel-Hébert, S. Veldhof, M. Webster, L.
Thuesen, D. Dudek, A bioabsorbable everolimus-eluting coronary stent system
(ABSORB): 2-year outcomes and results from multiple imaging methods, Lancet
373 (2009) 897–910.
[4] S.G. Ellis, D.J. Kereiakes, D.C. Metzger, R.P. Caputo, D.G. Rizik, P.S. Teirstein, M.R. Litt,
A. Kini, A. Kabour, S.O. Marx, J.J. Popma, R. McGreevy, Z. Zhang, C. Simonton, G.W.
Stone, ABSORB III Investigators, Everolimus-eluting bioresorbable scaffolds for coronary
artery disease, N. Engl. J. Med. 373 (20) (Nov 12 2015) 1905–1915, https://doi.org/10.
1056/NEJMoa1509038 (Epub 2015 Oct 12).
[5] R. Gao, Y. Yang, Y. Han, Y. Huo, J. Chen, B. Yu, X. Su, L. Li, H.C. Kuo, S.W. Ying, W.F.
Cheong, Y. Zhang, X. Su, B. Xu, J.J. Popma, G.W. Stone, ABSORB China Investigators,
Bioresorbable vascular scaffolds versus metallic stents in patients with coronary
artery disease: ABSORB China Trial, J. Am. Coll. Cardiol. 66 (21) (Dec 1 2015)
2298–2309, https://doi.org/10.1016/j.jacc.2015.09.054 (Epub 2015 Oct 12).
[6] T. Kimura, K. Kozuma, K. Tanabe, S. Nakamura, M. Yamane, T. Muramatsu, S. Saito, J.
Yajima, N. Hagiwara, K. Mitsudo, J.J. Popma, P.W. Serruys, Y. Onuma, S. Ying, S. Cao,
P. Staehr, W.F. Cheong, H. Kusano, G.W. Stone, ABSORB Japan Investigators, A
randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs.
everolimus-eluting metallic stents in patients with coronary artery disease:
ABSORB Japan, Eur. Heart J. 36 (47) (Dec 14 2015) 3332–3342, https://doi.org/10.
1093/eurheartj/ehv435 (Epub 2015 Sep 1).
[7] R. Kawaguchi, H. Tsurugaya, H. Hoshizaki, T. Toyama, S. Oshima, K. Taniguchi, Impact of
lesion calciﬁcation on clinical and angiographic outcome after sirolimus-eluting stent
implantation in real-world patients, Cardiovasc. Revasc. Med. 9 (2008) 2–8.
[8] I. Moussa, S.G. Ellis, M. Jones, D.J. Kereiakes, D. McMartin, B. Rutherford, R. Mehran,
M. Collins, M.B. Leon, J.J. Popma, M.E. Russell, G.W. Stone, Impact of coronary culprit
lesion calcium in patients undergoing paclitaxel-eluting stent implantation (a
TAXUS-IV sub study), Am. J. Cardiol. 96 (2005) 1242–1247.
[9] C.V. Bourantas, Y.J. Zhang, S. Garg, J. Iqbal, M. Valgimigli, S. Windecker, F.W. Mohr, S.
Silber, Vries Td, Y. Onuma, H.M. Garcia-Garcia, M.A. Morel, P.W. Serruys, Prognostic
implications of coronary calciﬁcation in patients with obstructive coronary artery
disease treated by percutaneous coronary intervention: a patient-level pooled
analysis of 7 contemporary stent trials, Heart 100 (15) (Aug 2014) 1158–1164.
[10] P. de Jaegere, H. Mudra, H. Figulla, Y. Almagor, S. Doucet, I. Penn, A. Colombo, C.
Hamm, A. Bartorelli, M. Rothman, M. Nobuyoshi, T. Yamaguchi, V. Voudris, C.
DiMario, S. Makovski, D. Hausmann, S. Rowe, S. Rabinovich, M. Sunamura, G.A.
van Es, Intravascular ultrasound-guided optimized stent deployment. Immediate
and 6 months clinical and angiographic results from the multicenter ultrasound
stenting in coronaries study (MUSIC Study), Eur. Heart J. 19 (1998) 1214–1223.
[11] H. Otake, J. Shite, J. Ako, T. Shinke, Y. Tanino, D. Ogasawara, T. Sawada, N. Miyoshi, H.
Kato, B.K. Koo, Y. Honda, P.J. Fitzgerald, K. Hirata, Local determinants of thrombus
formation following sirolimus-eluting stent implantation assessed by optical coherence
tomography, J. Am. Coll. Cardiol. Intv. 2 (2009) 459–466.
[12] R. Diletti, A. Karanasos, T. Muramatsu, S. Nakatani, N.M. Van Mieghem, Y. Onuma,
S.T. Nauta, Y. Ishibashi, M.J. Lenzen, J. Ligthart, C. Schultz, E. Regar, P.P. de Jaegere,Please cite this article as: J.M. Fam, et al., Impact of calcium on procedura
scaffolds - A prospective..., Int J Cardiol (2017), https://doi.org/10.1016/j.iP.W. Serruys, F. Zijlstra, R.J. van Geuns, Everolimus-eluting bioresorbable vascular
scaffolds for treatment of patients presenting with ST-segment elevation myocardial
infarction: BVS STEMI ﬁrst study, Eur. Heart J. 35 (12) (Mar 2014) 777–786, https://
doi.org/10.1093/eurheartj/eht546 (Epub 2014 Jan 6).
[13] C.M. Felix, J.M. Fam, R. Diletti, Y. Ishibashi, A. Karanasos, B.R. Everaert, N.M. van
Mieghem, J. Daemen, P.P. de Jaegere, F. Zijlstra, E.S. Regar, Y. Onuma, R. van Geuns,
Mid- to long-term clinical outcomes of patients treated with the everolimus-eluting
bioresorbable vascular scaffold: the BVS expand registry, JACC Cardiovasc. Interv. 9
(16) (Aug 22 2016) 1652–1663, https://doi.org/10.1016/j.jcin.2016.04.035 (Epub
2016 Jul 27).
[14] D.E. Cutlip, S. Windecker, R. Mehran, A. Boam, D.J. Cohen, G.A. van Es, et al., Clinical
end points in coronary stent trials: a case for standardized deﬁnitions, Circulation
115 (2007) 2344–2351.
[15] S. Basavarajaiah, T. Naganuma, A. Latib, A. Colombo, Can bioabsorbable scaffolds be
used in calciﬁed lesions? Catheter. Cardiovasc. Interv. 84 (1) (Jul 1 2014) 48–52,
https://doi.org/10.1002/ccd.24939 (Epub 2013 Aug 31).
[16] A. Seth, V. Ravisekar, U. Kaul, Use of ‘Guideliner’ catheter to overcome failure of
delivery of Absorb™ Bioresorbable Vascular Scaffold in calciﬁed tortuous coronary
lesions: technical considerations in ‘Real World Patients’, Indian Heart J. 66 (4)
(Jul–Aug 2014) 453–458, https://doi.org/10.1016/j.ihj.2014.05.019.
[17] T. Miyazaki, V.F. Panoulas, K. Sato, A. Latib, Colombo A1. Bioresorbable vascular scaf-
folds for heavily calciﬁed lesions: how to tackle the rugged passage? J. Invasive
Cardiol. 27 (8) (Aug 2015) E167–8.
[18] S. Tanimoto, P.W. Serruys, L. Thuesen, D. Dudek, B. de Bruyne, B. Chevalier, J.A.
Ormiston, Comparison of in vivo acute stent recoil between the bioabsorbable
everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium
coronary stent: insights from the ABSORB and SPIRIT trials, Catheter. Cardiovasc.
Interv. 70 (2007) 515–523.
[19] J.A. Ormiston, B. Webber, B. Ubod, M.W. Webster, J. White, Absorb everolimus-
eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deploy-
ment, side branch dilatation and post-dilatation strategies, EuroIntervention 10
(2015) 1169–1177.
[20] S.Y. Choi, B. Witzenbichler, A. Maehara, A.J. Lansky, G. Guagliumi, B. Brodie, M.A.
Kellett Jr., O. Dressler, H. Parise, R. Mehran, G.D. Dangas, G.S. Mintz, G.W. Stone,
Intravascular ultrasound ﬁndings of early stent thrombosis after primary percutane-
ous intervention in acute myocardial infarction: a harmonizing outcomes with
revascularization and stents in acute myocardial infarction (HORIZONS-AMI)
substudy, Circ. Cardiovasc. Interv. 4 (3) (Jun 2011) 239–247.
[21] Antonios Karanasos, Nicolas M. Van Mieghem, Nienke van Ditzhuijzen, Cordula
Felix, Joost Daemen, Anouchska Autar, Yoshinobu Onuma, Mie Kurata, Roberto
Diletti, Marco Valgimigli, Floris Kauer, Heleen van Beusekom, Peter de Jaegere,
Felix Zijlstra, Robert-Jan van Geuns, Evelyn Regar, Angiographic and optical coher-
ence tomography insights into bioresorbable scaffold thrombosis. A single-center
experience, Circ. Cardiovasc. Interv. 8 (5) (May 2015) https://doi.org/10.1161/
CIRCINTERVENTIONS.114.002369 (pii: e002369).
[22] G. Longo, F. Granata, D. Capodanno, Y. Ohno, C.I. Tamburino, P. Capranzano, A. La
Manna, B. Francaviglia, G. Gargiulo, C. Tamburino, Anatomical features and manage-
ment of bioresorbable vascular scaffolds failure: a case series from the GHOST
registry, Catheter. Cardiovasc. Interv. (Jan 8 2015) https://doi.org/10.1002/ccd.
25819 (Epub ahead of print).
[23] V.F. Panoulas, T. Miyazaki, K. Sato, T. Naganuma, A. Sticchi, H. Kawamoto, F. Figini, A.
Chieffo, M. Carlino, M. Montorfano, A. Latib, A. Colombo, Procedural outcomes of
patients with calciﬁed lesions treated with bioresorbable vascular scaffolds,
EuroIntervention 11 (12) (Mar 2016) 1355–1362, https://doi.org/10.4244/
EIJY15M03_11.
[24] H. Kawamoto, N. Ruparelia, A. Latib, T. Miyazaki, K. Sato, A. Tanaka, T.
Naganuma, A. Sticchi, A. Chieffo, M. Carlino, M. Montorfano, A. Colombo,
Expansion in calciﬁc lesions and overall clinical outcomes following bioresorb-
able scaffold implantation optimized with intravascular ultrasound, Catheter.
Cardiovasc. Interv. (Aug 22 2016) https://doi.org/10.1002/ccd.26725 (Epub
ahead of print).
[25] Ming Jiang Fam, J.N. van Der Sijde, A. Karanasos, C. Felix, R. Diletti, N. van
Mieghem, P. de Jaegere, F. Zijlstra, R. Jan van Geuns, E. Regar, Comparison of
acute expansion of bioresorbable vascular scaffolds versus metallic drug-
eluting stents in different degrees of calciﬁcation: an optical coherence tomog-
raphy study, Catheter. Cardiovasc. Interv. (Oct 7 2016) https://doi.org/10.1002/
ccd.26676.
[26] M. Ohya, K. Kadota, Y. Sotomi, K. Kozuma, K. Tanabe, M. Uematsu, T. Kawasaki, Y.
Morino, T. Tobaru, K. Nakao, K. Tachibana, K. Kishi, Y. Shibata, S. Ying, H. Kusano,
G.W. Stone, J.J. Popma, Y. Onuma, P.W. Serruys, T. Kimura, Impact of lesion calciﬁcation
on angiographic outcomes after Absorb everolimus-eluting bioresorbable vascular
scaffold implantation: an observation from the ABSORB Japan trial, EuroIntervention
(Nov 8 2016) https://doi.org/10.4244/EIJ-D-16-00359 (pii: EIJ-D-16-00359. Epub
ahead of print).
[27] A. Colombo, V.F. Panoulas, After 3 decades, at long last, a new device to deal with
calciﬁc lesions, JACC Cardiovasc. Interv. 7 (2014) 519–520.
[28] S. Basavarajaiah, T. Naganuma, A. Latib, A. Colombo, Can bioabsorbable scaffolds be
used in calciﬁed lesions? Catheter. Cardiovasc. Interv. 84 (2014) 48–52.
[29] K. Yamaji, L. Räber, S. Windecker, What determines long-term outcomes using fully
bioresorbable scaffolds - the device, the operator or the lesion? EuroIntervention
(Jan 26 2017) https://doi.org/10.4244/EIJV12I14A277 (pii: EIJV12I14A277. Epub
ahead of print).
[30] Patrick W. Serruys, Yoshinobu Onuma, Dmax for sizing, PSP-1, PSP-2, PSP-3 or OCT
guidance: interventionalist's jargon or indispensable implantation techniques
for short- and long-term outcomes of Absorb BRS? EuroIntervention (Mar 2 2017)
https://doi.org/10.4244/EIJY17M02_01 (pii: EIJY17M02_01. Epub ahead of print).l and clinical outcomes in lesions treated with bioresorbable vascular
jcard.2017.08.046
8 J.M. Fam et al. / International Journal of Cardiology xxx (2017) xxx–xxx[31] S. Cassese, R.A. Byrne, G. Ndrepepa, S. Kufner, J. Wiebe, J. Repp, H. Schunkert, M.
Fusaro, T. Kimura, A. Kastrati, Everolimus-eluting bioresorbable vascular scaffolds
versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled
trials, Lancet 387 (10018) (Feb 6 2016) 537–544, https://doi.org/10.1016/S0140-
6736(15)00979-4 (Epub 2015 Nov 17).
[32] G.W. Stone, R. Gao, T. Kimura, et al., 1-year outcomes with the Absorb bioresorbable
scaffold in patients with coronary artery disease: a patient-level, pooled meta-
analysis, Lancet 387 (2016) 1277–1289.
[33] Joanna J. Wykrzykowska, Robin P. Kraak, Sjoerd H. Hofma, Rene J. van der Schaaf, E.
Karin Arkenbout, Alexander J. IJsselmuiden, Joëlle Elias, Ivo M. van Dongen, Ruben
Y.G. Tijssen, Karel T. Koch, Jan Baan, Jr., M. Marije Vis, Robbert J. de Winter, Jan J.
Piek, Jan G.P. Tijssen, and Jose P.S. Henriques, for the AIDA Investigators*. Bioresorbable
scaffolds versus metallic stents in routine PCI. N. Engl. J. Med. https://doi.org/10.1056/
NEJMoa1614954.
[34] R.J. van Geuns, C. Tamburino, J. Fajadet, et al., Self-expanding versus balloon-
expandable stents in acute myocardial infarction: results from the APPOSITION II
study: self-expanding stents in ST-segment elevation myocardial infarction, JACC
Cardiovasc. Interv. 5 (12) (2012) 1209–1219, https://doi.org/10.1016/j.jcin.2012.
08.016.
[35] S. Puricel, F. Cuculi, M. Weissner, A. Schmermund, P. Jamshidi, T. Nyffenegger, H.
Binder, H. Eggebrecht, T. Münzel, S. Cook, T. Gori, Bioresorbable coronary scaffold
thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms,
and predictors, J. Am. Coll. Cardiol. 67 (8) (Mar 1 2016) 921–931, https://doi.org/10.
1016/j.jacc.2015.12.019.
[36] J.P. Giblett, A.J. Brown, H. Keevil, C. Jaworski, S.P. Hoole, N.E. West, Implantation of
bioresorbable vascular scaffolds following acute coronary syndrome is associated
with reduced early neointimal growth and strut coverage, EuroIntervention 12 (6)
(Aug 20 2016) 724–733, https://doi.org/10.4244/EIJV12I6A117.
[37] D. Capodanno, D.J. Angiolillo, Antiplatelet therapy after implantation of bioresorbable
vascular scaffolds: a review of the published data, practical recommendations, and
future directions, JACC Cardiovasc. Interv. 10 (5) (Mar 13 2017) 425–437, https://doi.
org/10.1016/j.jcin.2016.12.279.Please cite this article as: J.M. Fam, et al., Impact of calcium on procedura
scaffolds - A prospective..., Int J Cardiol (2017), https://doi.org/10.1016/j.i[38] A. Karanasos, N. Van Mieghem, N. van Ditzhuijzen, C. Felix, J. Daemen, A. Autar, Y.
Onuma, M. Kurata, R. Diletti, M. Valgimigli, F. Kauer, H. van Beusekom, P. de Jaegere,
F. Zijlstra, R.J. van Geuns, E. Regar, Angiographic and optical coherence tomography
insights into bioresorbable scaffold thrombosis: single-center experience, Circ.
Cardiovasc. Interv. 8 (5) (May 2015) https://doi.org/10.1161/CIRCINTERVENTIONS.
114.002369 (pii: e002369).
[39] C.M. Felix, Y. Onuma, J.M. Fam, R. Diletti, Y. Ishibashi, A. Karanasos, B.R. Everaert,
N.M. van Mieghem, J. Daemen, P.P. de Jaegere, F. Zijlstra, E.S. Regar, R.J. van Geuns,
Are BVS suitable for ACS patients? Support from a large single center real live registry,
Int. J. Cardiol. 218 (Sep 1 2016) 89–97, https://doi.org/10.1016/j.ijcard.2016.05.037
(Epub 2016 May 13).
[40] G.N. Levine, E.R. Bates, J.A. Bittl, R.G. Brindis, S.D. Fihn, L.A. Fleisher, C.B. Granger, R.A.
Lange, M.J. Mack, L. Mauri, R. Mehran, D. Mukherjee, L.K. Newby, P.T. O'Gara, M.S.
Sabatine, P.K. Smith, S.C. Smith Jr., ACC/AHA guideline focused update on duration
of dual antiplatelet therapy in patients with coronary artery disease: a report of the
American College of Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines, J. Am. Coll. Cardiol. 68 (10) (2016) 1082–1115, https://doi.org/10.
1016/j.jacc.2016.03.513 (2016 Sep 6. Epub 2016 Mar 29).
[41] C.M. Felix, G.J. Vlachojannis, A.J.J. IJsselmuiden, J.M. Fam, P.C. Smits, W. Lansink, R.
Diletti, F. Zijlstra, E.S. Regar, E. Boersma, Y. Onuma, R.J.M. van Geuns, Potentially in-
creased incidence of scaffold thrombosis in patients treated with Absorb BVS who
terminated DAPT before 18 months, EuroIntervention 13 (2) (2017) e177–e184,
https://doi.org/10.4244/EIJ-D-17-00119.
[42] C.M. Felix, G.J. Vlachojannis, A.J. IJsselmuiden, Y. Onuma, R.J. van Geuns, Very late scaf-
fold thrombosis in Absorb BVS: association with DAPT termination? JACC. Cardiovasc.
Interv. 10 (6) (Mar 27 2017) 625–626, https://doi.org/10.1016/j.jcin.2017.01.015.
[43] Y. Onuma, S. Tanimoto, P. Ruygrok, J. Neuzner, J.J. Piek, A. Seth, J.J. Schofer, G.
Richardt, M. Wiemer, D. Carrie, L. Thuesen, C. Dorange, K. Miquel-Hebert, S.
Veldhof, P.W. Serruys, Efﬁcacy of everolimus eluting stent implantation in patients
with calciﬁed coronary culprit lesions: two-year angiographic and three-year clinical
results from the SPIRIT II study, Catheter. Cardiovasc. Interv. 76 (2010) 634–642.l and clinical outcomes in lesions treated with bioresorbable vascular
jcard.2017.08.046
